Skip to main content

Advertisement

Table 4 Optimal CMV-derived HLA class I restricted CTL epitopes

From: Simultaneous assessment of cytotoxic T lymphocyte responses against multiple viral infections by combined usage of optimal epitope matrices, anti- CD3 mAb T-cell expansion and "RecycleSpot"

Protein HLA Restriction Sequence Position Reference
pp65 B35 IPSINVHHY 123–131 [56]
pp65 B35 DDVWTSGSDSDEELV 397–411 [57]
pp65 B35 VFPTKDVAL 187–195 [17]
pp65 B38 PTFTSQYRIQGKL 367–379 [17]
pp65 B7 TPRVTGGGAM 417–426 [57]
pp65 B7 RPHERNGFTVL 265–275 [17]
pp65 A1 YSEHPTFTSQY 363–373 [17]
pp65 A1101 SVLGPISGHVLK 13–24 [17]
pp65 A2402 FTSQYRIQGKL 369–379 [17]
pp65 A68 FVFPTKDVALP 186–196 [17]
pp65 A2 NLVPMVATV 495–503 [57]
pp65 A2 VLGPISGHV 14–22 [58]
pp65 A2 MLNIPSINV 120–128 [58]
pp65 B44 EFFWDANDIY 512–521 [57]
pp65 A2402 VYALPLKML 113–121 [59]
pp65 A2402/Cw0401 QYDPVAALF 341–349 [60, 61]
pp65 B5201 QMWQARLTV 155–163 [62]
pp65 A0207 RIFAELEGV 522–530 [61]
pp65 A1101 ATVQGQNLK 501–509 [61]
pp65 B1501 KMQVIGDQY 215–223 [61]
pp65 B4001 CEDVPSGKL 232–240 [61]
pp65 B40 HERNGFTVL 267–275 [61]
pp65 B4006 AELEGVWQPA 525–534 [61]
pp65 B4403 SEHPTFTSQY 364–373 [61]
pp65 B5101 DALPGPCI 545–552 [61]
pp65 Cw0102 RCPEMISVL 7–15 [61]
pp65 Cw0801 VVCAHELVC 198–206 [61]
pp65 Cw1202 VAFTSHEHF 294–302 [61]
pp65 A33 SVNVHNPTGR 91–100 [63]
pp150 A0301 TTVYPPSSTAK 945–955 [17]
pp150 A68 QTVTSTPVQGR 792–802 [17]
IE B7 CRVLCCYVL 309–317 [64]
IE A2 YILEETSVM 315–323 [65]
IE B18 ELKRKMIYM 199–207 [65]
IE B18 CVETMCNEY 279–287 [65]
IE B18 DEEDAIVAY 379–387 [65]
IE B18 SDEEEAIVAYTL 378–389 [56]
GB A2 FIAGNSAYEYV 618–628 [66]